Bicocca Open Archive

Logo unimib boa
CORTESI, PAOLO ANGELO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.966
EU - Europa 5.378
AS - Asia 2.013
AF - Africa 26
SA - Sud America 23
OC - Oceania 19
Continente sconosciuto - Info sul continente non disponibili 12
Totale 17.437
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.788
IT - Italia 1.412
DE - Germania 851
CN - Cina 715
IE - Irlanda 665
SE - Svezia 643
SG - Singapore 566
RU - Federazione Russa 463
UA - Ucraina 355
HK - Hong Kong 345
GB - Regno Unito 279
CA - Canada 165
FI - Finlandia 147
DK - Danimarca 144
FR - Francia 138
AT - Austria 90
IN - India 83
TR - Turchia 78
VN - Vietnam 74
ID - Indonesia 59
NL - Olanda 40
BE - Belgio 38
CH - Svizzera 27
IR - Iran 22
CZ - Repubblica Ceca 18
ES - Italia 18
KR - Corea 18
AU - Australia 14
BR - Brasile 12
EU - Europa 11
RO - Romania 10
MX - Messico 9
PK - Pakistan 9
BG - Bulgaria 8
JP - Giappone 8
PH - Filippine 8
NO - Norvegia 7
PT - Portogallo 6
GR - Grecia 5
NZ - Nuova Zelanda 5
PL - Polonia 5
CL - Cile 4
ET - Etiopia 4
GH - Ghana 4
NG - Nigeria 4
AR - Argentina 3
BD - Bangladesh 3
DZ - Algeria 3
SC - Seychelles 3
TH - Thailandia 3
TW - Taiwan 3
UZ - Uzbekistan 3
ZA - Sudafrica 3
AE - Emirati Arabi Uniti 2
BZ - Belize 2
EC - Ecuador 2
EG - Egitto 2
IQ - Iraq 2
KE - Kenya 2
MD - Moldavia 2
MK - Macedonia 2
MY - Malesia 2
OM - Oman 2
A1 - Anonimo 1
AZ - Azerbaigian 1
CO - Colombia 1
GE - Georgia 1
HN - Honduras 1
HR - Croazia 1
HU - Ungheria 1
IL - Israele 1
JO - Giordania 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LI - Liechtenstein 1
LK - Sri Lanka 1
MA - Marocco 1
ME - Montenegro 1
NP - Nepal 1
PE - Perù 1
SK - Slovacchia (Repubblica Slovacca) 1
VG - Isole Vergini Britanniche 1
Totale 17.437
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.847
Fairfield 858
Woodbridge 832
Chandler 727
Houston 662
Dublin 640
Frankfurt am Main 577
Wilmington 559
Ashburn 539
Singapore 463
Milan 402
Jacksonville 380
Seattle 360
Dearborn 345
Hong Kong 335
New York 330
Cambridge 280
Princeton 278
Nanjing 142
Altamura 128
Lawrence 124
Santa Clara 108
Vienna 86
Shanghai 78
San Diego 62
Lachine 60
Helsinki 57
Beijing 53
Jakarta 53
Andover 51
London 48
Nanchang 47
Rome 45
Dong Ket 43
Shenyang 40
Toronto 40
Guangzhou 38
Boardman 36
Tianjin 35
Fremont 33
Ottawa 30
Brussels 28
Hebei 28
Jiaxing 28
Lissone 27
Falls Church 25
Jinan 25
Lappeenranta 24
Los Angeles 24
Redmond 24
Bologna 23
Zhengzhou 23
Changsha 22
Hangzhou 22
Verona 22
Ningbo 20
Washington 20
Pune 19
Munich 18
Chicago 17
Kocaeli 17
San Jose 17
Mountain View 16
Norwalk 16
Kunming 15
Parma 15
Boston 14
Legnano 13
Taizhou 13
Hefei 12
Monza 11
Bonndorf 10
Carate Brianza 10
Edmonton 10
Nürnberg 10
Perugia 10
San Mateo 10
Dallas 9
Huizen 9
Montréal 9
Naples 9
Bergamo 8
Brno 8
Palermo 8
Phoenix 8
Prague 8
Tappahannock 8
Brescia 7
Buffalo 7
Central 7
Florence 7
Madrid 7
Paris 7
San Francisco 7
Slough 7
Busto Arsizio 6
Foggia 6
Hounslow 6
Indianapolis 6
Kiev 6
Totale 12.679
Salva come PNG Salva come JPEG
Nome #
Costs and effects of cardiovascular risk reclassification using the ankle-brachial index (ABI) in addition to the Framingham risk scoring in women 308
Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors 287
Clinical outcome indicators in chronic hepatitis B and C: A primer for value-based medicine in hepatology 287
Cost and Cost Effectiveness of Treatments for Psoriatic Arthritis: A Systematic Literature Review 267
Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 236
Optimising the clinical strategy for autoimmune liver diseases: Principles of value-based medicine 231
Trattamento con Sofosbuvir e Ribavirina nei pazienti hcv-positivi listati per il trapianto di fegato: un analisi di costo-efficacia 217
Trends in cardiovascular diseases burden and vascular risk factors in Italy: The Global Burden of Disease study 1990–2017 211
P1169 : Outcome indicators in primary sclerosing cholangitis: Interim analysis of the value-based medicine in hepatology study 191
Value-based outcome indicators in the management of hepatocellular carcinoma: Clinical test in a large multicenter study (VBMH study) 190
P0811 : Sofosbuvir-based direct-acting antivirals treatment for elderly chronic hepatitis C patients: A cost-effectiveness analysis 188
The optimal timing of hepatitis C therapy in liver transplant-eligible patients: Cost-effectiveness analysis of new opportunities 185
Health Related Quality of Life in the Major Liver Conditions 180
Outcome indicators in primary sclerosing cholangitis: Interim analysis of the value-based medicine in hepatology study 180
Generation and performance of value-based outcome indicators in liver disease: The multicenter V.B.M.H. study 178
Cost-Effectiveness and Budget Impact of Emicizumab Prophylaxis in Haemophilia A Patients with Inhibitors 178
Outcome Indicators in Primary Sclerosing Cholangitis: Interim Analysis Of The Value-Based Medicine In Hepatology (VBMH) Study 176
Outcome indicators in liver cirrhosis: Application of value-based medicine in a large multicenter study (VBMH study) 173
Global, regional, and national burden of congenital heart disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 172
Health related quality of life in chronic liver diseases 170
Characteristics of patients with Chronic Hepatitis C who have failed past treatment or who have never been treated: How much room left for Interferon? 168
Should new antiviral treatments be considered in elderly Chronic Hepatitis C patients? 168
The Impact of Type of Liver Conditions on the Patients’ Health Related Quality of Life 167
Should Sofosbuvir-Based All-Oral Treatment Be Considered In Elderly Chronic Hepatitis C Patients? 167
The impact of liver disease on the health-related quality of life 166
Value-based outcome indicators in liver cirrhosis: validation in a large multicenter study (VBMH study) 165
PGI36 Relationship Between Clinical Severity and Health Related Quality of Life in Chronic Liver Diseases 164
Sofosbuvir-based all-oral treatment for elderly chronic hepatitis C patients: A cost-effectiveness analysis 164
Sustainability of the Italian National Health Service 164
Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017 164
Economic Burden of Urticaria Requiring Hospitalization: Analysis from an Administrative Database 163
Il burden delle polmoniti: analisi dai database amministrativi (DENALI) della regione Lombardia. 161
Sacubitril/valsartan in heart failure with reduced ejection fraction: cost and effectiveness in the Italian context 161
Global, regional, and national incidence, prevalence, and years lived with disability for 354 Diseases and Injuries for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017 160
Italy's health performance, 1990–2017: findings from the Global Burden of Disease Study 2017 160
Measurement of clinical outcomes and quality of life indicators as a new value-based approach to liver cirrhosis management 159
Population and fertility by age and sex for 195 countries and territories, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017 159
Benefits in pain perception, ability function and health-related quality of life in patients with failed back surgery syndrome undergoing spinal cord stimulation in a clinical practice setting 157
Generation and Performance of Outcome Indicators in Liver Cirrhosis: The Value Based Medicine in Hepatology Study (V.B.M.H.) 156
PGI31 Health Care Indicators to Measure Quality of Care in Patients with Liver Diseases 154
The Burden of Severe Hypoglicaemias and Diabetes Ketoacidosis: A Population-Based Study 153
A Comparison Between The Health-Related Quality Of Life Reported By The General Population And By Patients With Major Liver Diseases 151
Economic Burden Of Stroke: Analysis From An Administrative Database 149
The socioeconomic burden of patients affected by hemophilia with inhibitors 149
The Cost-Effectiveness Of Sofosbuvir And Ribavirin Treatment In Hcv-Infected Patients Listed For Liver Transplantation 148
Management of treatment-naïve chronic hepatitis C genotype 1 patients: A cost-effectiveness analysis of treatment options 147
Effective but costly: How to tackle difficult trade-offs in evaluating health improving technologies in liver diseases 147
Costs and effectiveness of influenza vaccination: A systematic review 147
COVID-19 outbreak impact on anticoagulants utilization: an interrupted time-series analysis using healthcare administrative databases 146
A value-based approach to the management of patients with liver cirrhosis through the systematic measurement of clinical outcome and quality of life indicators 145
Direct-acting antivirals combination for elderly patients with chronic hepatitis C: A cost-effectiveness analysis 143
Value-based approach to hepatocellular carcinoma: outcome indicators tested in a large multicenter study (VBMH study) 140
Management of chronic hepatitis C (Chc) genotype 1 treatment-naïve patients in an era of rising opportunities and costs: A cost-effectiveness analysis 139
Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016 139
Utilization of disease modifying agents in multiple sclerosis: from an Italian administrative database. 137
Management of Chronic hepatitis C (CHC) Genotype 1 treatment-naive patients in an era of rising opportunities and costs - A cost-effectiveness analysis of treatment options 137
Immune tolerance induction in patients with haemophilia a and inhibitors: Effectiveness and cost analysis in an European Cohort (The ITER Study) 135
Cost-effectiveness analysis of pharmacokinetic-driven prophylaxis vs. standard prophylaxis in patients with severe haemophilia A 135
Epidemiology and Direct Health Care Costs of Diabetic Retinopathy: Results From a Population-Based Study 134
Use of health care administrative databases to estimate the burden of breast cancer. 130
Impatto dei farmaci anti virali ad azione diretta sulla cura dei pazienti con epatite C: un approccio di value-based medicine 129
Liver transplantation for patients with acute-on-chronic liver failure (ACLF) in Europe: results of the ELITA/EF-CLIF collaborative study (ECLIS) 125
Italian population-based values of EQ-5D health states 124
Cost-effectiveness of Sofosbuvir plus Ledipasvir Antiviral Treatment for Elderly Patients with Chronic Hepatitis C Genotype 1 124
Preferenze della popolazione italiana per gli stati di salute dell'EQ-5D 123
Incidence of inhibitors to recombinant factor VIII products – A meta-analysis of 1,852 previously untreated patients 123
Global, regional, and national age-sex-specific mortality and life expectancy, 1950-2017: A systematic analysis for the Global Burden of Disease Study 2017 123
Use of health care administrative databases to estimate incidence of foot complications in diabetes patients 122
Epidemiologic And Economic Burden Attributable To Atrial Fibrillation From Administrative Data 122
The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 122
Utilization of antispasticity drugs in multiple sclerosis: analysis from an Italian administrative database 120
Meta-analysis on incidence of inhibitors in patients with haemophilia A treated with recombinant factor VIII products 119
Protective role of tacrolimus, deleterious role of age and comorbidities in liver transplant recipients with Covid-19: results from the ELITA/ELTR multi-center European study 119
Use of healthcare administrative databases to estimate the burden of diabaetes mellitus: a population-based study 119
Health related quality of life norm data of the general population in Italy: Results using the EQ-5D-3L and EQ-5D-5L instruments 118
Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study 118
Epidemiologic and Economic Burden Attributable to First Spinal Fusion Surgery: Analysis from an Italian Administrative Database 117
Use of health care administrative databases to estimate the burden of multiple sclerosis: a population-based study 116
Health economic models in hemophilia A and utility assumptions from a clinician's perspective 113
Systematic review: economic evaluations of HCV screening in the direct-acting antivirals era 113
Long-term costs and outcomes in psoriatic arthritis patients not responding to conventional therapy treated with tumour necrosis factor inhibitors: An extension of the Psoriatic Arthritis Cost Evaluation (PACE) study 111
Patients’ and physicians’ needs, experiences and preferences in the treatment of rght ventricular outflow tract dysfunction. 108
Models of The Impact of Major Liver Diseases on Eq-5d Visual Analogue Scale and Utility-Index: Convergences and Divergences 108
Utilization of disease modifying agents in multiple sclerosis: analysis from an Italian administrative database. 107
Clinical epidemiology of hand eczema in patients accessing dermatological reference centres: Results from Italy 107
Patients’, physicians’, nurses’, and pharmacists’ preferences on the characteristics of biologic agents used in the treatment of rheumatic diseases 106
Cost-effectiveness of new direct-acting antivirals to prevent post-liver transplant recurrent hepatitis 106
Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry 105
Sofosbuvir and ribavirinin in HCV-infected patients listed for liver transplantation: A cost-effectiveness analysis 104
Difference in health related quality of life of chronic liver diseases and general population 104
Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 104
Thromboembolic event rate in patients exposed to anti-inhibitor coagulant complex: a meta-analysis of 40-year published data 103
Applicazione della value-based medicine nella valutazione della cura dei pazienti affetti da epatite. 103
2020 position statement and recommendations of the European Liver and Intestine Transplantation Association (ELITA): management of hepatitis B virus-related infection before and after liver transplantation 100
Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017 98
Is there a difference in inhibitor incidence with recombinant products? A meta-analysis of 2000 previously untreated patients 98
Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 97
Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in Patients with Coronary and Peripheral Artery Diseases in Italy 97
Antidepressants Drug Use during COVID-19 Waves in the Tuscan General Population: An Interrupted Time-Series Analysis 96
Use of health care administrative databases to estimate the health care burden of bone or bone marrow metastatic disease in breast cancer patients: a population-based study. 95
Totale 14.769
Salva come PNG Salva come JPEG
Categoria #
all - tutte 65.166
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 65.166
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.533 0 0 188 225 248 362 422 296 330 212 206 44
2020/20212.589 178 117 297 239 258 182 230 239 202 231 148 268
2021/20221.868 137 182 253 178 130 146 64 121 109 129 106 313
2022/20233.149 327 896 275 271 212 452 57 195 222 49 100 93
2023/20242.714 98 119 93 149 295 645 397 119 233 114 146 306
2024/20251.294 352 716 226 0 0 0 0 0 0 0 0 0
Totale 18.545